mRNA 1345
Alternative Names: mRESVIA; mRNA-1345; Respiratory syncytial virus vaccine - Moderna TherapeuticsLatest Information Update: 10 Apr 2025
At a glance
- Originator Moderna Therapeutics
- Class RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Registered Respiratory syncytial virus infections
- Phase I Metapneumovirus infections
Most Recent Events
- 31 Mar 2025 Registered for Respiratory syncytial virus infections (In the elderly, Prevention) in Australia (IM)
- 28 Feb 2025 Registered for Respiratory syncytial virus infections (Prevention, In the elderly) in United Kingdom (IM)
- 28 Feb 2025 Registered for Respiratory syncytial virus infections in United Arab Emirates, Taiwan, Qatar (IM) before February 2025